『In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!』のカバーアート

In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!

In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: what is adaptive biobehavioral control for AID systems? Omnipod 5 launches iOS app with Dexcom G7 compatability and a comic book(?!), Tandem and Abbott announce new partnership, Katie Bone is back on American Ninja Warrior, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The American Diabetes Association Scientific Sessions kicks off in a week – we expect as always to get a lot of information! I’m not covering in person this year, but I’ll bring you any big announcements. And we’ll do a wrap up In the News the following week. -- XX UVA with something new.. technology that allows an artificial pancreas system to adapt to users’ changing needs – and lets users adjust the settings – beyond what’s commercially available now. They’re calling this “adaptive biobehavioral control,” the technology helps fine-tune UVA’s artificial pancreas every two weeks, giving users a virtual tool to test different ways to manage their blood sugar using their own data. In a six-month study, participants using the technology spent more time in a healthy blood-sugar range, rising from 72% to 77%, and saw a small but meaningful drop in their average blood-sugar levels. While automated insulin delivery systems help users better manage Type 1 diabetes, adaptive biobehavioral control technology is designed to improve blood-sugar control during the day, when fluctuations occur more frequently due to meals and physical activity. This new technology uses “digital twins,” computer models simulating how a person’s body processes sugar. The models help the artificial pancreas keep up with changes in the user’s body and habits and give users a way to interact with the system. For example, users can try different settings, like how much insulin is released overnight, using the simulation before applying them in real life. https://news.virginia.edu/content/uvas-artificial-pancreas-uses-digital-twin-tech-improve-diabetes-control XX Five years later after COVID-19 his the US, a new study shows that there is a connection with type 1 diabetes triggers. This is new research from the University of Utah published in the journal ImmunoInformatics. With T1D in particular, a COVID infection appears to trigger the immune system of certain people who have a prior susceptibility to the condition to subsequently develop T1D symptoms, the new study suggests. University of Utah researchers hypothesize that COVID is leading to T1D diagnoses in a roundabout way as the virus presents the body with “molecular mimics,” or fragments of COVID proteins that bear an uncanny resemblance to those beta cell antigens. When a person is infected with COVID, the immune system not only attacks fragments of the viral protein but also attacks fragments of beta cell antigens because they look so similar and get mistaken for each other, explains lead study author Julio Facelli, Ph.D., a distinguished professor of biomedical informatics at University of Utah Health in Salt Lake City. That means that in people who are already predisposed to T1D, there may be a simultaneous autoimmune reaction involving the destruction of healthy beta cells, spurring the onset of type 1 diabetes. Both 2022 and 2024 research indicates that there has been a significant increase in new onset type 1 diabetes following the start of the COVID pandemic. It’s difficult to estimate just how many cases may have been triggered by COVID because numerous viruses, including rotavirus, measles, mumps, and rubella, can spark an autoimmune response that activates T1D, according to the 2022 research published in Immunology & Cell Biology. Again, it’s important to note that researchers don’t believe a COVID infection is causing diabetes, but rather, triggering it, in the same way certain environmental factors are believed to trigger immune-mediated conditions like Crohn’s and psoriasis. “ https://...

In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。